

Does repeat placental growth factor blood sample testing reduce harm from pre-eclampsia to babies?

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
10/10/2019	No longer recruiting	<input checked="" type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
25/11/2019	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
12/01/2026	Pregnancy and Childbirth	

Plain English summary of protocol

Background and study aims

Pre-eclampsia is a condition occurring only in pregnancy, thought to be caused by the way the placenta implants into the wall of the womb. Women with pre-eclampsia can suffer from high blood pressure, problems with their kidneys, liver and blood clotting. The problems with the placenta can mean that the baby's growth is affected. In some cases the baby can be stillborn. Once diagnosed, the only cure is to deliver the baby. If pre-eclampsia occurs before 37 weeks of pregnancy, women may need to be admitted to hospital to have treatment and monitoring for complications, whilst planning for safe delivery of the baby. Some women become unwell very quickly and need to have their babies delivered; others have long stays in hospital. It can be difficult to identify women at high-risk of severe complications of pre-eclampsia. This study looks at the levels of a protein produced by the placenta called Placenta Growth Factor (PIGF). Women with suspected pre-eclampsia can have a simple blood test for this protein. Studies have shown that women with very low PIGF levels are at greater risk of severe pre-eclampsia and stillbirth. However, it is not known how PIGF levels change over time. When pre-eclampsia is suspected, it is difficult to predict how severely a woman and her baby will be affected. The aim of this study is to find out whether using repeated blood samples can help to reduce severe complications for babies, and for women.

Who can participate?

Pregnant women aged 18 or over suspected of having pre-eclampsia

What does the study involve?

If a woman agrees to take part, she will be asked to sign a consent form, and details about her and her pregnancy will be put into a secure computer database. This will also be noted in her hospital maternity records. The study computer will then select for her to have repeat PIGF-based blood tests with the results known or not known to her, her doctors and her midwives while she is pregnant. There will be a 50:50 chance of being in either study group. She will then have routine bloods to test for pre-eclampsia that will include her first PIGF-based test. Her doctor will then use the results of these tests to guide her care following their hospital standard practice. Depending on the result of the blood tests (including the PIGF-based test), the doctors

and midwives will decide if a woman needs to be admitted to hospital or how often they will need to see her again in her pregnancy to make sure she and the baby are okay. When she is asked to have repeat blood tests for routine follow up care, we will ask her for an extra 10 ml or two teaspoons of blood for a PIgf-based test. Depending on which study group she is in, the doctors and midwives will be given or not given the result of the PIgf-based test. If the doctors and midwives are given the PIgf-based test result, they can use this to guide ongoing care, in addition to following their hospital standard practice. If the doctors and midwives are not given the PIgf-based test results ongoing antenatal care will be exactly the same as if women were not taking part in the study. Women will only be asked to provide an extra blood sample for this study once per week or once every two weeks (depending on the result of the first test) and only for a maximum of four times during their pregnancy.

What are the possible benefits and risks of participating?

The first PARROT study showed that some women may spend less time in hospital, and if they have an abnormal result they may benefit from their doctors and midwives having more information about their pre-eclampsia condition. There are no expected serious side effects to having the blood tests and participants will be having blood tests as part of their normal clinical care.

Where is the study run from?

1. Guy's and St Thomas' NHS Foundation Trust (UK)
2. Manchester University NHS Foundation Trust (UK)
3. Leeds Teaching Hospitals NHS Trust (UK)
4. Liverpool Women's NHS Foundation Trust (UK)
5. Royal United Hospitals Bath NHS Foundation Trust (UK)
6. Bradford Teaching Hospitals NHS Foundation Trust (UK)
7. St George's University Hospitals NHS Foundation Trust (UK)
8. Kingston Hospital NHS Foundation Trust (UK)
9. Chelsea and Westminster Hospital NHS Foundation Trust (UK)
10. North Bristol NHS Trust (UK)
11. University Hospitals Bristol NHS Foundation Trust (UK)
12. Imperial College Healthcare NHS Trust (UK)
13. NHS Lothian (UK)
14. Ashford and St Peter's Hospitals NHS Foundation Trust (UK)
15. Croydon Health Services NHS Trust (UK)
16. Norfolk and Norwich University Hospitals NHS Foundation Trust (UK)
17. University College London Hospitals NHS Foundation Trust (UK)
18. Nottingham University Hospitals NHS Trust (UK)
19. Warrington and Halton Hospitals NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

April 2019 to March 2023

Who is funding the study?

1. Moulton Charitable Trust (UK)
2. Tommy's Baby Charity (UK)

Who is the main contact?

Dr Louise Webster

louise.m.webster@kcl.ac.uk

Contact information

Type(s)

Public

Contact name

Dr Louise Webster

Contact details

St. Thomas's Hospital
249 Westminster Bridge Road
London
United Kingdom
SE1 7EH
+44 (0)20 7188 3639
louise.m.webster@kcl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

265824; CPMS: 43092

Study information

Scientific Title

Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia

Acronym

PARROT-2

Study objectives

Repeat PIgf-based testing, in women presenting with suspected preterm pre-eclampsia, reduces adverse perinatal outcomes (perinatal death/neonatal unit admission).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/11/2019, East of England - Cambridge East Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; Tel: +44 (0)207 104 8101; Email: NRESCommittee.EastofEngland-CambridgeEast@nhs.net), ref: 19/EE/0322

Study design

Multi-centre randomized controlled trial

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Pre-eclampsia

Interventions

Multi-centre RCT of revealed versus concealed repeat PIgf-based testing in women presenting with suspected pre-eclampsia between 22+0 and 35+6 weeks' gestation. The trial will be conducted in at least 15 maternity units across England. Recruitment will run for approximately 18 months in total.

All women participating in the trial will have an initial revealed PIgf-based test, allowing the clinician to formulate an individualised management plan.

Randomisation will be via a secure web-based platform (MedSciNet) with 50% of women assigned to revealed repeat PIgf-based testing and 50% of women assigned concealed repeat PIgf-based testing.

For the trial, the women will be asked to provide one extra tube of blood (as far as possible at the same time as clinical blood samples) up to four times during the rest of their pregnancy as per the schedule below. The results of the repeat PIgf-based test will be revealed to the health care professionals and the women in the intervention arm and used in addition to the other clinical features to inform ongoing management plan integrated with the NICE Hypertension in Pregnancy Guideline. The results of the repeat tests will be concealed in the usual care arm. It is recognised that some women will only provide one sample; from previous studies it is anticipated that most women will provide two samples as the majority of women will be delivered within that time interval.

For both the revealed repeat testing and concealed repeat testing groups, the repeat sampling strategy will be based on the first PIgf test result as follows:

1. If PIgf ≤ 100 pg/ml (including women <12 pg/ml) or sFlt-1/PIgf ratio >38 , i.e. at higher risk, sampling will be weekly whilst attending for clinical review.
2. If PIgf >100 pg/ml or sFlt-1/PIgf ratio ≤ 38 (lower risk) and asymptomatic of pre-eclampsia, sampling will be every two weeks (+/- 7 days) whilst attending for routine antenatal checks. If a woman presents ≥ 7 days from last sample and is symptomatic, an additional sample can be taken and reported.

Women will only be asked to provide repeat samples while they are still pregnant and pregnancy outcome data for mother and baby will be collected by the site research teams from care records without the need for further review in person of the participants.

Intervention Type

Other

Primary outcome(s)

Composite of:

1. Stillbirth defined as death of a fetus after 24 weeks' gestation and before birth collected by 6 weeks post birth
2. Early neonatal death defined as death occurring within the first 7 days of life collected by 6 weeks post birth
3. Neonatal unit admission defined as admission of the neonate to the neonatal unit and captured within the first 6 weeks from birth

Key secondary outcome(s)

Additional fetal and neonatal outcomes:

1. Late neonatal death defined as neonatal death occurring between 7 and 28 days after birth and captured from hospital records by 6 weeks post birth
2. Need for respiratory support on Neonatal Unit defined as the need for CPAP/high flow /endotracheal ventilation and recorded by 6 weeks post birth
3. Gestational age at delivery measured in days and recorded by 6 weeks post birth
4. Birthweight centile <10th calculated using recorded birth weight and using the Intergrowth 21 birthweight centile calculator and calculated by the trial statistician prior to data analysis

Added 07/07/2022:

5. Survival to discharge without severe morbidity: defined as survival to neonatal discharge without any of the following: bronchopulmonary dysplasia, retinopathy of prematurity, severe necrotising enterocolitis, brain injury, late-onset sepsis

Maternal secondary outcomes (between enrollment and delivery):

1. Proportion of women diagnosed with pre-eclampsia defined using the ISSHP definition and captured by 6 weeks post birth
2. Severe adverse maternal outcome composite defined by the fullPIERS consensus and captured by 6 weeks post birth
3. Systolic blood pressure ≥ 160 mmHg measured during routine blood pressure readings captured in maternity records and occurring on at least one occasion between study enrolment and birth of the baby
4. Concealed first repeat PIgf-based test performance (with comparison against currently utilised tests) for clinically indicated delivery for diagnosed pre-eclampsia within 14 days measured in peripheral blood samples at 1 to 3 weeks post study enrollment and analysed following completion of the trial

Health economic outcomes:

1. Perinatal: intensive care, high dependency and special care unit days measured as total of these days and captured by 6 weeks post birth
2. Maternal: antenatal outpatient attendances and inpatient days; intensive care unit use measured as total numbers of each of these antenatal care episodes and captured by 6 weeks post birth

Completion date

31/03/2023

Eligibility

Key inclusion criteria

1. Women aged 18 years or more between 22+0 and 35+6 weeks' gestation with clinical suspicion of pre-eclampsia
2. Viable singleton pregnancy
3. Able to give written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

55 years

Sex

Female

Total final enrolment

1252

Key exclusion criteria

Confirmed preterm pre-eclampsia at presentation

Date of first enrolment

06/12/2019

Date of final enrolment

30/09/2022

Locations

Countries of recruitment

United Kingdom

England

Scotland

Study participating centre

Guy's and St Thomas' NHS Foundation Trust

St. Thomas's Hospital

249 Westminster Bridge Road

London
England
SE1 7EH

Study participating centre

Manchester University NHS Foundation Trust
Cobbett House
Oxford Road
Manchester Greater
Manchester
England
M13 9WL

Study participating centre

Leeds Teaching Hospitals NHS Trust
Beckett Street
Leeds
England
LS9 7TF

Study participating centre

Liverpool Women's NHS Foundation Trust
Crown Street
Liverpool
England
L8 7SS

Study participating centre

Royal United Hospitals Bath NHS Foundation Trust
Combe Park
Bath
England
BA1 3NG

Study participating centre

Bradford Teaching Hospitals NHS Foundation Trust
Duckworth Lane
Bradford
England
BD9 6RJ

Study participating centre
St George's University Hospitals NHS Foundation Trust
Blackshaw Road
Tooting
London
England
SW17 0QT

Study participating centre
Kingston Hospital NHS Foundation Trust
Galsworthy Road
London
England
KT2 7QB

Study participating centre
Chelsea and Westminster Hospital NHS Foundation Trust
369 Fulham Road
London
England
SW10 9NH

Study participating centre
North Bristol NHS Trust
Southmead Road
Westbury-on-Trym
Bristol
England
BS10 5NB

Study participating centre
University Hospitals Bristol NHS Foundation Trust
Marlborough Street
Bristol
England
BS13NU

Study participating centre

Imperial College Healthcare NHS Trust

St. Mary's Hospital
Praed Street
London
England
W2 1NY

Study participating centre

NHS Lothian
Waverley Gate
2-4 Waterloo Place
Edinburgh
Scotland
EH1 3EG

Study participating centre

Ashford and St Peter's Hospitals NHS Foundation Trust
Guildford Road
Surrey
England
KT160PZ

Study participating centre

Croydon Heath Services NHS Trust
London Road
Thornton Heath
Surrey
England
CR7 7YE

Study participating centre

Norfolk and Norwich University Hospitals NHS Foundation Trust
Colney Lane
Colney
Norwich
England
NR4 7UY

Study participating centre

University College London Hospitals NHS Foundation Trust
250 Euston Road

London
England
NW1 2PG

Study participating centre

Nottingham University Hospitals NHS Trust
Derby Road
Nottingham
England
NG7 2UH

Study participating centre

Warrington and Halton Hospitals NHS Foundation Trust
Lovely Lane
Warrington
England
WA5 1QG

Sponsor information

Organisation

King's College London

ROR

<https://ror.org/0220mzb33>

Organisation

Guy's and St Thomas' NHS Foundation Trust

Funder(s)

Funder type

Charity

Funder Name

Moulton Charitable Trust

Funder Name

Tommy's Baby Charity

Alternative Name(s)**Funding Body Type**

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Louise Webster (louise.m.webster@kcl.ac.uk) and Lucy Chappell (lucy.chappell@kcl.ac.uk).

Type of data: quantitative

When the data will become available and for how long: 01/12/2022

By what access criteria data will be shared including with whom: to be determined at a later date

For what types of analyses, and by what mechanism: to be determined at a later date

Whether consent from participants was obtained: not applicable

Comments on data anonymisation: Data would only be supplied in fully anonymised format

Any ethical or legal restrictions: not aware of any

Any other comments: no

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		08/02/2024	12/02/2024	Yes	No
Results article		06/05/2024	07/05/2024	Yes	No
Results article	Health economic assessment	06/01/2026	12/01/2026	Yes	No
Protocol article		02/09/2022	05/09/2022	Yes	No
HRA research summary		28/06/2023	No		No